Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Saturday, February 18, 2017

Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration

Since this is a carotenoid you could get a two-fer if you are Cacausian.

This Vegetable Will Make You Look 50% More Attractive - Cacausians

 Assuming that your doctor reads and applies research. FAT CHANCE OF THAT!
http://link.springer.com/article/10.1007/s11357-017-9958-x

  • Bethany Grimmig
  • Seol-Hee Kim
  • Kevin Nash
  • Paula C. Bickford
  • R. Douglas Shytle
  • Bethany Grimmig
    • 1
  • Seol-Hee Kim
    • 1
  • Kevin Nash
    • 2
  • Paula C. Bickford
    • 1
    • 3
  • R. Douglas Shytle
    • 1
  1. 1.Department of Neurosurgery and Brain Repair, Center of Excellence for Aging and Brain Repair, Morsani College of MedicineUniversity of South FloridaTampaUSA
  2. 2.Byrd Alzheimer’s Institute, Department of Molecular Pharmacology and Physiology, Morsani College of MedicineUniversity of South FloridaTampaUSA
  3. 3.James A Haley VA HospitalTampaUSA
Review Article
DOI: 10.1007/s11357-017-9958-x
Cite this article as:
Grimmig, B., Kim, SH., Nash, K. et al. GeroScience (2017). doi:10.1007/s11357-017-9958-x
  • 2 Downloads

Abstract

Astaxanthin (AXT) is a carotenoid with multiple health benefits. It is currently marketed as a health supplement and is well known for its antioxidant capacity. Recent evidence has emerged to suggest a broad range of biological activities. The interest in this compound has increased dramatically over the last few years and many studies are now applying this molecule across many disease models. Results from the current research are beginning to come together to suggest neuroprotective properties including anti-inflammatory, anti-apoptotic, and antioxidant effects, as well as the potential to promote or maintain neural plasticity. These emergent mechanisms of actions implicate AXT as a promising therapeutic agent for neurodegenerative disease. This review will examine and extrapolate from the recent literature to build support for the use of AXT in mitigating neuropathy in normal aging and neurodegenerative disease.

No comments:

Post a Comment